Allergen immunotherapy (AIT) reduces symptoms and medication use associated with allergic rhinitis with or without conjunctivitis and allergic asthma. Although several AIT guidelines exist, there remain unanswered questions about AIT that are relevant to everyday practice. Our objective was to prepare an evidence-based overview addressing the practical aspects of AIT in clinical practice based on published evidence and the experience of international experts in the field. Topics covered include interpretation and translation of clinical trial data into everyday clinical practice (eg, allergen doses and treatment duration), assessment of risk and treatment of local and systemic allergic reactions, recommendations for improvement of AIT guidelines, and identification of appropriate data for seeking regulatory approval, to name a few. Many informational gaps in AIT practice need further evaluation as products and practices evolve.

变应原免疫疗法（AIT）可减少伴有或不伴有结膜炎和变应性哮喘的变应性鼻炎的症状和用药。尽管存在一些AIT准则，但是仍然存在与日常实践相关的AIT未解决问题。我们的目标是根据已发表的证据和国际专家在该领域的经验，针对临床实践中AIT的实际情况编写循证概述。涵盖的主题包括将临床试验数据解释和翻译为日常临床实践（例如，过敏原剂量和治疗持续时间），风险评估和局部和全身性过敏反应的治疗，AIT指南改进建议以及寻找合适的数据以寻求监管批准，仅举几例。